Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron
CEO, Mike Lampron
Source: Mach7 Technologies
Market Herald logo


Be the first with the news that moves the market
  • Mach7 Technologies (M7T) receives purchase orders for its software and services totalling $3.6 million from US-based Trinity Health
  • The latest order supplements Trinity’s previous deal with M7T to purchase the company’s eUnity Enterprise Viewer in November 2020
  • M7T will provide Trinity a full diagnostic picture archiving and communication system (PACS) solution with a maximum value of $15.6 million over seven years
  • Shares are up 4.52 per cent to $1.04 each at 1:24 pm AEST

Mach7 Technologies (M7T) has received purchase orders for its software and services from Trinity Health totalling $3.6 million.

Based in Michigan, Trinity claims to be one of the largest multi-institutional Catholic healthcare delivery systems in the US, servicing communities at 92 hospitals and 100 continuing-care locations across 22 states.

In a statement today M7T said Trinity had placed orders for its Mach7 Enterprise Imaging Platform, eUnity Diagnostic Views, eUnity Enterprise Viewer and Mach7 Universal Worklist.

The company expects revenue from these orders to be recognised this financial year, with a further $3.8 million in support fees expected over the next seven years, taking the total contract value to $7.4 million.

The purchase follows the seven-year contract signed by the parties for the eUnity Enterprise Viewer, which was announced to the ASX in November last year.

In light of Trinity’s subsequent purchase of several other software and services from M7T, the company will now supply Trinity a full diagnostic picture archiving and communication system (PACS) solution.

According to Mach7, the total maximum value of the PACS solution is $15.6 million over seven years, including the original Enterprise Viewer contract.

The company’s CEO Mike Lampron said he was excited about the opportunity to [work] with Trinity Health.

“I believe the full Mach7 solution is well-positioned to deliver on the strategic objectives of Trinity’s Unified Clinical Imaging Platform Strategy and I look forward to being a part of their initiative,” he said.

Shares were up 4.52 per cent to $1.04 each at 1:24 pm AEST.

M7T by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.